Recent progress of Src SH2 and SH3 inhibitors as anticancer agents

Current Medicinal Chemistry

Volumn 17, Issue 12, 2010, Pages 1117-1124

  Lu, X L ^a   Cao, X ^b   Liu, X Y ^a   Jiao, B H ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY   (China)

Author keywords

Inhibitor; Nonpeptide; Peptidomimetic; Progress; Protein tyrosine kinases; SH2; SH3; Src kinases

Indexed keywords

2 AMINOQUINOLINE; ACETYLPHOSPHOTYROSINE GLUTAMYLGLUTAMYLISOLEUCINE; CAFTARIC ACID; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; PEPTIDOMIMETIC AGENT; PROTEIN SH2; PROTEIN SH3; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SALVIANOLIC ACID A; SALVIANOLIC ACID B; UCS 15A; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; DRUG RESEARCH; ENZYME INHIBITION; HUMAN; IC 50; NONHUMAN; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; METABOLISM; SRC HOMOLOGY DOMAIN;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; SRC HOMOLOGY DOMAINS; SRC-FAMILY KINASES;

EID: 77950648340     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790827861     Document Type: Article

References (45)

1. Adjei, AA; Hidalgo, M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol., 2005, 23, 5386-5403. (Pubitemid 46206992)
2. Ma, W.W.; Adjei, A.A. Novel agents on the horizon for cancer therapy. CA Cancer J. Clin., 2009, 59, 111-137.
3. Haskell, M.D.; Slack, J.K.; Parsons, J.T.; Parsons, S.J. c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem. Rev., 2001, 101, 2425-2440.
4. Frame, M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta, 2002, 1602, 114-130.
5. Cartwright, C.A.; Kamps, M.P.; Meisler, A.I.; Pipas, J.M.; Eckhart, W. pp60c-Src activation in human colon carcinoma. J. Clin. Invest., 1989, 83, 2025-2033
6. Cartwright, C.A.; Meisler, A.I.; Eckhart, W. Activation of the pp60c-srcprotein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA, 1990, 87, 558-562 (Pubitemid 20051409)
7. Biscardi, J.S.; Belsches, A.P.; Parsons, S.J. Characterization of humanepidermal growth factor receptor and c-Src interactions in humanbreast tumor cells. Mol. Carcinog., 1998, 21, 261-272
8. Verbeek, B.S.; Vroom, T.M.; Adriaansen-Slot, S.S.; Ottenhoff-Kalff, A.E.; Geertzema, J.G.; Hennipman, A.; Rijksen G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol., 1996, 180, 383-388
9. Egan, C.; Pang, A.; Durda, D.; Cheng, H.C.; Wang, J.H.; Fujita, D.J..Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine530. Oncogene, 1999, 18, 1227-1237
10. Lutz, M.P.; Esser, I.B.; Flossmann-Kast, B.B.; Vogelmann, R.; Luhrs, H.; Friess, H., Buchler, M.W., Adler, G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem. Biophys. Res. Commun., 1998, 243, 503-508 (Pubitemid 28414054)
11. Mazurenko, N.N.; Kogan, E.A.; Zborovskaya, I.B.; Kisseljov, F.L. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer, 1992, 28, 372-377
12. Wiener, J.R.; Windham, T.C.; Estrella, V.C.; Parikh, N.U.; Thall, P.F.; Deavers, M.T., BastJr, R.C.; Mills, G..; Gallick G.E. Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol. Oncol., 2003, 88, 73-79
13. Kumble, S.; Omary, M.B.; Cartwright, C.A. Triadafilopoulos G. Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology, 1997, 112, 348-356
14. Takeshima, E.; Hamaguchi, M.; Watanabe, T.; Akiyama, S.; Kataoka, M.; Ohnishi, Y.; Xiao H.; Nagai Y.; Hiroshi H. Aberrant elevation of tyrosine-specific phosphorylation in human gastric cancer cells. Jpn. J. Cancer Res., 1991, 82, 1428-1435
15. Niu, G.; Bowman, T.; Huang, M.; Shivers, S.; Reintgen, D.; Daud, A.; Chang, A.; Kraker, A.; Jove, R.; Yu, H. Roles of activated Src and Stat3 signaling in melanoma tumorcell growth. Oncogene, 2002, 21, 7001-7010 (Pubitemid 35252974)
16. Bjelfman, C.; Meyerson, G.; Cartwright, C.A.; Mellstrom, K.; Hammerling, U.; Pahlman, S. Early activation of endogenous pp60 Src kinase activity during neuronal differentiation of cultured human neuroblastoma cells. Mol. Cell Biol., 1990, 10, 361-370 (Pubitemid 20028990)
17. Eliceiri, B.P.; Paul, R.; Schwartzberg, P.L.; Hood, J.D.; Leng, J.; Cheresh, D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell, 1999, 4, 915-924
18. Cao, X.; You, Q.D.; Li, Z.Y.; Wang, X.J.; Lu, X.Y.; Liu, X.R; Xu, D.; Liu, B. Recent progress of Src family kinase inhibitors as anti-cancer agents. Mini Rev. Med. Chem., 2008, 8(10), 1053-1063
19. Pawson, T.; Gish, G.D. SH2 and SH3 domains: from structure to function. Cell 1992, 71, 359-362
20. Botfield, M.C.; Green, J. Chapter 24. SH2 and SH3 domains: choreographers of multiple signaling pathways. Annu. Rep. Med. Chem., 1995, 30, 227-237
21. Park, J.;Fu, H.; Pei.D. Peptidyl aldehydes as reversible covalent inhibitors of Src homology 2 domains. Biochemistry, 2003, 42, 5159-5167
22. Zhou, S.Y.; Shoelson, S.E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W.G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R.J.; Neel, B.G.; Birge, R.B.; Fajardo, J.E.; Chou, M.M.; Hanafusa, H.; Schaffhausen, B.; Cantley, L.C. SH2 domains recognize specific phosphopeptide sequences. Cell, 1993, 72, 767-778
23. Davidson, J.P.; Lubman, O.; Rose, T.; Waksman, G.; Martin, S.F. Calorimetric and structural studies of 1, 2, 3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding. J. Am. Chem. Soc., 2002, 124, 205-215
24. Sundaramoorthi, R.; Siedem, C.; Vu, C.B.; Dalgarno, D.C.; Laird, E.C.; Botfield, M.C.; Combs, A.B.; Adams, S.E.; Yuan, R.W.; Weigele, M.; Narula, S.S. Selective inhibition of Src SH2 by a novel thiol-targeting tricarbonyl-modified inhibitor and mechanistic analysis by 1H/13C NMR spectroscopy. Bioorg. Med. Chem. Lett., 2001, 11, 1665-1669
25. Park, S.H.; Wona, T.; Leeb, K.H. Design and characterization of non-phosphopeptide inhibitors for Src family SH2 domains. Bioorg. Med. Chem. Lett., 2002, 12, 2711-2714
26. Nam, N.H.; Ye, G.F.; Sun, G.H.; Parang, K. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. J. Med. Chem., 2004, 47, 3131-3141 (Pubitemid 38702707)
27. Nam, N.H.; Pitts, R.L.; Sun, G.H.; Sardari, S.; Tiemo, A.; Xie, M.X.; Yana, B.F.; Parang, K. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2,5-lipoxygenase inhibitor. Bioorg. Med. Chem. Lett., 2004, 12, 779-782
28. Ye, G.F.; Schuler A.D.; Ahmadibeni, Y.; Morgan, J.R.; Faruqui, A.; Huang, K.Z.; Sun, G.Q.; Zebala, J.A.; Parang, K. Synthesis and evaluation of phosphopeptides containing iminodiacetate groups as binding ligands of the Src SH2 domain. Bioorg. Chem., 2009, 37, 133-142
29. Buchanan, J.L.; Bohacek, R.S.; Luke, G.P.; Hatada, M.; Lu, X.D.; Dalgamo, D.C.; Narua, S.S.; Yuan, R.; Holt, D.A. Structure-based design and synthesis of a novel class of Src SH2 inhibitors. Bioorg. Med. Chem. Lett., 1999, 9, 2353-2358
30. Src SH2 domain. Bioorg. Med. Chem. Lett., 2001, 11, 2319-2323
31. Shakespeare, W.C.; Bohacek, R.S.; Azimioara, M.D.; Macek, K.J.; Luke, G.P.; Dalgarno, D.C.; Hatada, M.H.; Lu, X.D.; Violette, S.M.; Bartlett, C.; Sawyer, T.K. Structure-based design of novel bicyclic nonpeptide inhibitors for the Src SH2 domain. J. Med. Chem., 2000, 43, 3815-3819
32. Lange, G.; Lesuisse, D.; Deprez, P.; Schoot, B.; Loenze, P.; Bénard, D.; Marquette, J.P.; Broto, P.; Sarubbi, E.; Mandine, E. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of pp60Src are identical to those for high affinity binding of full length inhibitors. J. Med. Chem., 2003, 46, 5184-5195 (Pubitemid 37414188)
33. Hur, E. M.; Choi, B.; Park, C.; Lee, J.; Park, D.; Yun, Y.; Lee, K. H.; Oh, J. E.; Ahn, C. S.; Lee, H. S.; Ahn, J. S; Jung, S. I. U.S. Patent 6,140, 363.
34. Won, J.; Hur, E. M.; Hur, Y.; Park, S.; Kang, M.; Choi, Y.; Park, C.; Lee, K. H.; Yun, Y. Rosmarinic acid inhibits TCR-induced T cell activation and proliferation in an Lck-dependent manner. Eur. J. Immunol., 2003, 33, 870-879 (Pubitemid 36546674)
35. Park, S.H.; Kang, S.H.; Lim, S.H.; Ohb, H.S.; Leeb, K.H. Design and synthesis of small chemical inhibitors containing different scaffolds for lck SH2 domain. Bioorg. Med. Chem. Lett., 2003, 13, 3455-3459
36. Bianca Sperl, Markus H.J.Seifert, Thorsten Berg Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains. Bioorg. Med. Chem. Lett., 2009, 19, 3305-3309
37. Ozanne, B.W.; Spence, H.J.; Mcgarry L.C.; Hennigan R.F. Transcription factors control invasion: AP-1 the first among equals. Oncogene, 2007, 26, 1-10.
38. Combs A.P.; Kapoor T.M.; Feng S.B.; Chen J.K.; Daude-Snow L.F., Schreiber S.L. Protein structre-based combinatorial chemistry: discovery of non-peptide binding elements to Src SH3 domain J. Am. Chem. Soc., 1996, 118, 287-288 (Pubitemid 3017427)
39. Feng S.B.; Kapoor T.M.; Shirai F.; Combs A.P.; Schreiber S.L. Molecular basis for the binding of SH3 ligands with non-peptide elements identified by combinatorial synthesis. Chem. Biol., 1996, 3: 661-670.
40. Sharma, S.V.; Oneyama, C.; Yamashita, Y.; Nakano, H.; Sugawara, K.; Hamada, M.; Kosaka, N; Tamaoki, T. UCS15A, a nonkinase inhibitor of Src signal transduction. Oncogene, 2001, 20, 2068-2079 (Pubitemid 32424001)
41. Fumagalli, S.; Totty, N.; Hsuan, J.; Courtneidge, S. A target for Src in mitosis. Nature, 1994, 368, 871-875
42. Oneyama, C.; Nakano, H.; Sharma, S.V. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene, 2002, 21, 2037-2050
43. Inglis, S.R.; Stojkoski, C.; Branson, K.M.; Cawthray, J.F.; Fritz, D.; Wiadrowski, E.; Pyke, S.M.; Booker, G.W. Identification and specificity studies of small-molecule ligands for SH3 protein domains. J. Med. Chem., 2004, 47, 5405-5417
44. Inglis, S.R.; Jones, R.K.; Booker, G.W.; Pyke, S.M. Synthesis of N-benzylated-2-aminoquinolines as ligands for the Tec SH3 domain. Bioorg. Med. Chem. Lett., 2006, 16, 387-390
45. Smith, J. A.; Jones, R. K.; Booker, G. W; and Pyke S. M. Sequential and Selective Buchwald-Hartwig Amination Reactions for the Controlled Functionalization of 6-Bromo-2-chloroquinoline: Synthesis of Ligands for the Tec Src Homology 3 Domain. J. Org. Chem., 2008, 73, 8880-8892.